JJKK 048 - CAS 1515855-97-6
Catalog number: 1515855-97-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
JJKK 048, a benzodioxol derivative, has been found to a MAGL inhibitor that could probably be significant in anticancer and anti-inflammatory studies. IC50: 0.4 nM.
JJKK048; JJKK-048; JJKK 048; MolPort-035-941-193; BDBM50065646; AKOS025142062; ZINC103287208; [4-[bis(1,3-benzodioxol-5-yl)methyl]piperidin-1-yl]-(1,2,4-triazol-1-yl)methanone
DMSO: 100 mM
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Quality Standard:
In-house standard
Canonical SMILES:
1.In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048).
Aaltonen N;Kedzierska E;Orzelska-Górka J;Lehtonen M;Navia-Paldanius D;Jakupovic H;Savinainen JR;Nevalainen T;Laitinen JT;Parkkari T;Gynther M J Pharmacol Exp Ther. 2016 Oct;359(1):62-72. doi: 10.1124/jpet.116.233114. Epub 2016 Jul 22.
Monoacylglycerol lipase (MAGL) is a serine hydrolase that acts as a principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG). In addition to terminating the signaling function of 2-AG, MAGL liberates arachidonic acid to be used as a primary source for neuroinflammatory prostaglandin synthesis in the brain. MAGL activity also contributes to cancer pathogenicity by producing precursors for tumor-promoting bioactive lipids. Pharmacological inhibitors of MAGL provide valuable tools for characterization of MAGL and 2-AG signaling pathways. They also hold great therapeutic potential to treat several pathophysiological conditions, such as pain, neurodegenerative disorders, and cancer. We have previously reported piperidine triazole urea, {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048), to be an ultrapotent and highly selective inhibitor of MAGL in vitro. Here, we characterize in vivo effects of JJKK-048. Acute in vivo administration of JJKK-048 induced a massive increase in mouse brain 2-AG levels without affecting brain anandamide levels. JJKK-048 appeared to be extremely potent in vivo. Activity-based protein profiling revealed that JJKK-048 maintains good selectivity toward MAGL over other serine hydrolases.
2.Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.
Aaltonen N;Savinainen JR;Ribas CR;Rönkkö J;Kuusisto A;Korhonen J;Navia-Paldanius D;Häyrinen J;Takabe P;Käsnänen H;Pantsar T;Laitinen T;Lehtonen M;Pasonen-Seppänen S;Poso A;Nevalainen T;Laitinen JT Chem Biol. 2013 Mar 21;20(3):379-90. doi: 10.1016/j.chembiol.2013.01.012.
Monoacylglycerol lipase (MAGL) terminates the signaling function of the endocannabinoid, 2-arachidonoylglycerol (2-AG). During 2-AG hydrolysis, MAGL liberates arachidonic acid, feeding the principal substrate for the neuroinflammatory prostaglandins. In cancer cells, MAGL redirects lipid stores toward protumorigenic signaling lipids. Thus MAGL inhibitors may have great therapeutic potential. Although potent and increasingly selective MAGL inhibitors have been described, their number is still limited. Here, we have characterized piperazine and piperidine triazole ureas that combine the high potency attributable to the triazole leaving group together with the bulky aromatic benzodioxolyl moiety required for selectivity, culminating in compound JJKK-048 that potently (IC50 < 0.4 nM) inhibited human and rodent MAGL. JJKK-048 displayed low cross-reactivity with other endocannabinoid targets. Activity-based protein profiling of mouse brain and human melanoma cell proteomes suggested high specificity also among the metabolic serine hydrolases.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related MAGL Products

CAS 1438416-21-7 MJN110

(CAS: 1438416-21-7)

MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor that modulates the synaptic processes. MJN110 has the potential for the treatment of a...

CAS 1101854-58-3 JZL184

(CAS: 1101854-58-3)

JZL 184 is the first selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 nM.

CAS 1221418-42-3 SAR629

(CAS: 1221418-42-3)

SAR-629 is a Monoglyceride lipase (MGL) inhibitor and can also be known as 2-arachidonoylglycerol (2-AG) degradation inhibitor. MGL is a serine hydrolase which ...

CAS 1881244-28-5 NF 1819

NF 1819
(CAS: 1881244-28-5)

NF 1819 is a selective irreversible β-lactam-based monoacylglycerol lipase inhibitor with IC50 values of 0.25 and 7.4 nM at rMAGL and hMAGL.

CAS 1680193-80-9 JZP 361

JZP 361
(CAS: 1680193-80-9)

JZP 361 is a reversible, potent and selective inhibitor of human recombinant MAGL (hMAGL) with IC50 value of 46 nM. It shows affinity for H1 receptors but shows...

CAS 1416133-89-5 JW 642

JW 642
(CAS: 1416133-89-5)

Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic p...

CAS 565460-15-3 URB602

(CAS: 565460-15-3)

URB602, a cell-permeable N-biphenyl carbamate compound, is a selective inhibitor of monoglycerol lipase (MGL). The IC50 = 28 μM and Km = 20 μM. It does not inhi...

CAS 1515855-97-6 JJKK 048

JJKK 048
(CAS: 1515855-97-6)

JJKK 048, a benzodioxol derivative, has been found to a MAGL inhibitor that could probably be significant in anticancer and anti-inflammatory studies. IC50: 0.4...

Chemical Structure

CAS 1515855-97-6 JJKK 048

Quick Inquiry

Verification code

Featured Items